Thermo Fisher will dedicate its newly installed training center, designed with industry-leading resources and technologies. The facility is equipped with virtual reality and augmented reality capabilities, which will mimic a real-world operating environment and equipment, and reduce the amount of training time by 50%.
The purpose built, state-of-the art facility will help address the growing demand for development supply chain services and will focus on high quality secondary packaging solutions for customers and their patients. The new site will provide clinical trial support services including GMP storage, local labeling, secondary packaging, comparator sourcing, and handling and distribution of ambient and cold chain clinical trial supplies through to returns management.
Thermo Fisher Scientific expanded capacity at the North American site for sterile drug products in Greenville, NC and will now perform non-GMP work to support clinical phase programs. The new development laboratory features two Lyostar3 freeze dryers with SMART technology that are capable of decreasing the number of runs required for lyophilization cycle development.
Vertex Pharmaceuticals Incorporated recently announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for the VX-445 (elexacaftor), tezacaftor and ivacaftor triple combination regimen
Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that a license agreement has been reached with Biotheus Inc. ("Biotheus"), a privately held Chinese company based in Zhuhai, Guangdong, China
"This new drug provides another option for the treatment of patients with community-acquired bacterial pneumonia, a serious disease," said Ed Cox, M.D., M.P.H., director of FDA's Office of Antimicrobial Products
A team at Scripps Research in Florida has discovered a biological system that manages cells’ response to opioid drug exposure. The unexpected discovery offers new ideas for improving the safety of the one of the most effective, and most abused, group of pain medications
Two Northwestern University scientists have received a $3.1M grant from the National Institute on Aging to collaborate and investigate drug therapies for amyotrophic lateral sclerosis (ALS)
GeneCentric Therapeutics, Inc. recently announced that it has acquired Select ImmunoGenomics, LLC, a Chapel Hill, NC-based provider of advanced immunogenomic, data analysis and biomarker development services to support the development of immuno-oncology drugs
The U.S. Food and Drug Administration today granted accelerated approval to Rozlytrek (entrectinib), a treatment for adult and adolescent patients whose cancers have the specific genetic defect, NTRK (neurotrophic tyrosine receptor kinase) gene fusion and for whom there are no effective treatments
|
|
|
|
|
|
|
|
|